Andrew P. Han
Andrew Han covers breaking news for GenomeWeb. He tracks companies in the sequencing and diagnostic markets.

Articles Authored by Andrew P. Han
10x Genomics, Vizgen Settle Global Patent Infringement Spat
Details, including whether any money exchanged hands or if any patent cross-licensing occurred, were not disclosed.
Unknown Effects of China Retaliation Cloud Illumina's 2025 Expectations After 2024 Revenue Decline
Premium
Fourth quarter sales in China were up 1 percent, as Illumina beat Wall Street estimates on the top and bottom lines.
Long Read-Based Fiber-seq Chromatin Accessibility Method Draws Academic, Commercial Interest
Premium
The method, which adds chromatin accessibility information to long-read whole-genome sequencing, is gaining momentum as more labs seek to implement it.
CZI, 10x Genomics, Ultima Genomics to Sequence 1 Billion Single Cells to Train AI Models
The project is also partnering with academic researchers, including Alexander Marson, director of the Gladstone-UCSF Institute of Genomic Immunology.
The method combines MERFISH with expansion microscopy to increase the volume of individual bacterial cells and reduce the density of RNA molecules inside.
US Patent Review Panel Invalidates 10x Genomics' Patent Claims After Parse Biosciences Challenge
Parse Biosciences, which has now triggered invalidation of three 10x Genomics patents in response to being sued for infringement, said it was a "significant legal victory."
Twist Bioscience Raises Fiscal 2025 Guidance as Q1 Revenues Rise 24 Percent
The synthetic biology and genomics company reported 24 percent year-over-year revenue growth in fiscal Q1, beating Wall Street expectations.
Church, Shendure Labs Team up to Probe Possibilities for Structural Variants in Mammalian Genomes
Premium
The authors of two newly published papers likened their method to Perturb-seq, except that it introduces structural variants instead of gene knockouts.
The paper shows how spatial biology technologies are helping researchers in fields where certain sample types were previously a barrier to progress.

CEO Christian Henry said he is hopeful seven Vega placements in Q4 and other product launches last year will help PacBio return to growth in 2025.